The study showed 76%of tumor samples were negative for PD-L1 expression, and the data suggest that the activity of immune checkpoint inhibitors (ICIs) may be impaired in NSCLC with mutations in the EGFR ex20ins (54), EGFR ex20ins mutations have reduced efficacy with ICIs (55). This evidence concerns the gene EGFR and non-small cell lung carcinoma.